Posted: May 12, 2008

Starpharma Reports Positive VivaGel Clinical Study Results

(Nanowerk News) Starpharma Holdings Limited today announced positive results of a clinical trial that achieved all its objectives demonstrating that 3% SPL7013 Gel (VivaGel®) was safe and well-tolerated in sexually abstinent women when administered vaginally, twice daily for 14 days.
Based on these results and existing supporting data, the product is deemed suitable for continued development as a topical microbicide for the prevention of HIV and genital herpes (HSV) and the exploration of other potential indications.  These findings support current and future clinical studies to assess the safety and efficacy of VivaGel® for genital herpes and HIV in sexually active women. The study enrolled 54 women in the U.S. and Kenya and was double blinded so that the participants, the investigators and study staff did not know who was receiving VivaGel® or placebo gel.
Blood tests (systemic laboratory parameters) showed no evidence of any treatment-related effects in study participants.  This finding was not surprising, given that consistent with previous clinical and non-clinical studies, there was no evidence of absorption of the active ingredient of VivaGel®, SPL7013, into the blood after vaginal application in this study.  Study participants also showed no evidence of any treatment-related effects on vaginal microflora.
No participant discontinued or was required to discontinue product use due to any adverse events during the trial.
An additional positive outcome was there was no statistical difference between the VivaGel® and placebo arms in the number of participants who experienced any sign or symptom including genitourinary (genital and urinary) signs or symptoms deemed to be associated with product use.  During the study, there were no serious adverse events reported, nor grade 3 or 4 adverse events.  Moderate (grade 2) genitourinary findings occurred in only three women receiving VivaGel® at the U.S. site.  All other genitourinary findings were reported as being mild (grade 1).
The incidence of genital signs and symptoms reported with VivaGel® in this study is in line with that reported for other topical vaginal products and markedly lower than that reported with nonoxynol-9 in similar studies.
Starpharma’s CEO, Dr Jackie Fairley said, “We are pleased to report that VivaGel® has met its safety and tolerability endpoints in this expanded safety study.  We look forward to moving ahead with further trials of the product - both in the HIV and HSV-2 programs and also potentially in additional applications of VivaGel® including other STIs and contraception.”
The clinical study was funded by the Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and conducted by DMID in collaboration with the Sexually Transmitted Infections Clinical Trials Group (STI-CTG).  This was the first study to be conducted under the U.S. Investigational New Drug application (IND) for VivaGel® for prevention of genital herpes.
VivaGel® is being developed as a topical vaginal microbicide for the prevention of HIV and genital herpes, and also shows promise as a contraceptive agent.  In addition, the company recently reported VivaGel® has activity against clinically relevant human papillomavirus (HPV).  Starpharma is also co-developing a VivaGel® coated condom with SSL International plc and one other unnamed market leading condom company.
  About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc in Michigan, USA.  Products based on SPL’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company’s lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
In the wider pharmaceutical field Starpharma has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).  More broadly the company is exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.
SPL has a comprehensive IP portfolio that comprises more than 224 patents/applications issued and pending across 56 patent families - a unique level of IP concentration among nanotechnology companies. Dendrimers: A type of precisely-defined, branched nanoparticle.  Dendrimers have applications in the medical, electronics, chemicals and materials industries.
Source: Starpharma
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: